Effect of eptifibatide, a glycoprotein IIb/IIIa antagonist, among diabetic patients following coronary stenting: Results from ESPRIT

被引：0
|
作者：
Labinaz, M
Madan, M
McGuire, DK
Batchelor, W
Saucedo, J
Pacchiana, C
Kitt, MM
O'Shea, JC
Talley, DJ
Liu, H
Timmis, S
Tcheng, JE
机构：
[1] Univ Ottawa, Inst Heart, Ottawa, ON, Canada
[2] Sunnybrook Hosp, Toronto, ON, Canada
[3] Duke Univ, Durham, NC USA
[4] Univ Toronto, Toronto, ON, Canada
[5] Univ Arkansas, Med Ctr, Little Rock, AR 72204 USA
[6] Duke Clin Res Inst, Durham, NC USA
[7] Cor Therapeut, San Francisco, CA USA
[8] Univ Arkansas, Little Rock, AR 72204 USA
[9] Jackson Madison Hosp, Jackson, TN USA
[10] William Beaumont Hosp, Royal Oak, MI 48072 USA
来源：
CIRCULATION | 2000年 / 102卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3215
引用
收藏
页码：665 / +
页数：2
相关论文
共 50 条
  • [41] Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes - Results from PURSUIT
    Akkerhuis, KM
    Deckers, JW
    Boersma, E
    Harrington, RA
    Stepinska, J
    Mahaffey, KW
    Wilcox, RG
    Lincoff, AM
    Keltai, M
    Topol, EJ
    Califf, RM
    Simoons, ML
    EUROPEAN HEART JOURNAL, 2000, 21 (05) : 371 - 381
  • [42] Effect of loading with Clopidogrel at the time of coronary stenting on platelet aggregation and glycoprotein IIb/IIIa expression and platelet-leukocyte aggregate formation
    Gurbel, PA
    Malinin, AI
    Callahan, KP
    Serebruany, VL
    O'Connor, CM
    AMERICAN JOURNAL OF CARDIOLOGY, 2002, 90 (03): : 312 - +
  • [43] Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting - The TARGET Trial
    Stone, GW
    Moliterno, DJ
    Bertrand, M
    Neumann, FJ
    Herrmann, HC
    Powers, ER
    Grines, CL
    Moses, JW
    Cohen, DJ
    Cohen, EA
    Cohen, M
    Wolski, K
    DiBattiste, PM
    Topol, EJ
    CIRCULATION, 2002, 105 (20) : 2347 - 2354
  • [44] Impact of clinical syndrome acuity on the differential response to two glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: The TARGET trial
    Stone, GW
    Moliterno, DJ
    Bertrand, M
    Neumann, FJ
    Herrmann, HC
    Powers, ER
    Grines, CL
    Cohen, DJ
    Cohen, EA
    Cohen, M
    Piedmonte, M
    DiBattiste, PM
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (05) : 22A - 22A
  • [45] The effect of glycoprotein IIb/IIIa inhibition on ST-segment resolution following successful primary percutaneous coronary interventions
    Uyarel, Huseyin
    Erdem, Ismail
    Dayi, Sennur Unal
    Kasikcioglu, Hulya
    Tartan, Zeynep
    Akgul, Ozgur
    Simsek, Dilek
    Karabulut, Ahmet
    Gurdogan, Muhammed
    Okmen, Ertan
    Cam, Nese
    TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2005, 33 (04): : 204 - 211
  • [46] Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes - Observations from the platelet IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial
    Lauer, MA
    Houghtaling, PL
    Peterson, JG
    Granger, CB
    Bhatt, DL
    Sapp, SK
    Simoons, ML
    Harrington, RA
    Topol, EJ
    Lincoff, AM
    CIRCULATION, 2001, 104 (23) : 2772 - 2777
  • [47] Impact of glycoprotein IIb/IIIa inhibitors on outcomes of diabetic patients undergoing percutaneous coronary interventions with sirolimus-eluting stents
    Nikolsky, Eugenia
    Holmes, David R.
    Mehran, Roxana
    Dangas, George
    Schampaert, Erick
    Morice, Marie-Claude
    Schofer, Joachim
    Sousa, J. Eduardo
    Donohoe, Dennis
    Moses, Jeffrey W.
    Leon, Martin B.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (09) : 32B - 33B
  • [48] Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial (vol 354, pg 2019, 1999)
    Topol, EJ
    LANCET, 2000, 355 (9209): : 1104 - 1104
  • [49] Glycoprotein IIb/IIIa antagonists during carotid artery stenting: Results from the carotid artery stenting (CAS) registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausarzte (ALKK)
    Zahn, R.
    Ischinger, T.
    Hochadel, M.
    Mark, B.
    Zeymer, U.
    Jung, J.
    Schramm, A.
    Hauptmann, K. E.
    Seggewiss, H.
    Janicke, I.
    Mudra, H.
    Senges, J.
    CLINICAL RESEARCH IN CARDIOLOGY, 2007, 96 (10) : 730 - 737
  • [50] Stenting without predilatation (direct stenting) prevents myonecrosis in patients with non-ST elevation acute coronary syndrome and glycoprotein IIb/IIIa inhibitor treatment.
    Sghaier, M
    Angioi, M
    Vançon, AC
    Moulin, F
    Mock, L
    Piquemal, R
    Ethévenot, G
    AMERICAN JOURNAL OF CARDIOLOGY, 2002, 90 (6A): : 164H - 165H
12345